BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Henlius Licenses Ipilimumab Biosimilar HLX13 to Sandoz in $301M Global Deal

Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations Henlius to receive $...

April 30, 2025 | News

Australia’s Viral Vector Manufacturing Facility Selects SYSPRO Cloud ERP to Drive Quality and Compliance in Biopharma Manufacturing

Viral Vector Manufacturing Facility Pty Ltd (VVMF) has selected SYSPRO for its Cloud ERP system. VVMF is Australia’s first viral...

April 29, 2025 | News

University of Melbourne and Thermo Fisher Forge Strategic Partnership to Advance Research Across Healthcare, Manufacturing, and Sustainability

Researchers will be able to access cutting-edge tools to tackle society’s most pressing challenges across healthcare, manufacturing and sustainabilit...

April 22, 2025 | News

Transverse Medical Completes First Patient Series in Feasibility Study of POINT-GUARD™ CEP Device in Australia

Transverse Medical Inc. is excited to announce the completion of the first series of patients under its Feasibility Clinical Study at the prestigious Victo...

April 22, 2025 | News

Clarity Pharmaceuticals Secures Commercial-Scale Copper-64 Supply Agreement with Nusano Ahead of U.S. Product Launch

Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or 64Cu) isotope. The 190,000 squa...

April 18, 2025 | News

TGA Approves IFINWIL® for High-Risk Neuroblastoma Treatment in Australia

Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL® (eflornit...

April 17, 2025 | Regulatory

Clarity Begins Phase II Dosing in SECuRE Trial for Prostate Cancer with Enhanced 67Cu-SAR-bisPSMA Formulation

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GB...

April 16, 2025 | News

Telix Reports Positive Preliminary Results from IPAX-Linz Study of TLX101 in Recurrent High-Grade Glioma

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...

April 16, 2025 | News

Atmo Biosciences Secures Full Ownership of Core IP for Ingestible Gas-Sensing Capsule

Atmo secures full ownership of core IP for its ingestible gas-sensing capsule • RMIT University transfers all patents and IP in exchange for an eq...

April 15, 2025 | News

Telix Doses First Patient in ZOLAR Phase 1 Trial for Advanced Soft Tissue Sarcoma

Telix Pharmaceuticals Limited announces that a first patient has been dosed in the Phase 1 ZOLAR trial of TLX300-CDx (89Zr-olaratumab) in patients wit...

April 02, 2025 | News

Ractigen Reports Promising Phase I Data for First-in-Class saRNA Therapy RAG-01 in Bladder Cancer

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, announced the presentation of...

March 25, 2025 | News

Parse Biosciences Welcomes South Australian Genomics Centre as First Certified Service Provider in Asia-Pacific

Parse Biosciences, a leader in scalable and affordable single-cell sequencing, is delighted to welcome the South Australian Genomics Centre (SAGC)&nbs...

March 24, 2025 | News

Telix Secures FDA Approval for Gozellix® to Expand PSMA-PET Imaging Access in Prostate Cancer

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administrat...

March 21, 2025 | News

Alamar Biosciences Expands APAC Presence with Five New Distribution Partnerships

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new dis...

March 20, 2025 | News

Stay Connected